### Effect of a Clinical Pathway on Outcome of Children with Hemolytic Anemia

Thesis

Submitted for Partial Fulfillment of Doctorate in (Pediatric Nursing)

By

#### **Amira Adel Mohamed Nassar**

Assistant Lecturer at South Valley University

Faculty of Nursing
Ain Shams University
2013

### **Effect of a Clinical Pathway on Outcome of Children with Hemolytic Anemia**

Thesis

Submitted for Partial Fulfillment of Doctorate in (Pediatric Nursing science)

Supervisors

Prof. Dr. **Iman Ibrahim Abd El-**Moneim

Professor& Chairmen of Pediatric Nursing Department Ain Shams University

Prof. Dr. **Mohsen Saleh Elalfy** 

Professor& Chairmen of Pediatric Medicine Department Ain Shams University

Dr.

**Madiha Amin Morsy** 

Assistant Professor of Pediatric Nursing Faculty of Nursing Ain Shams University

2013



First and foremost, I feel always indebted to **ALLAH**, the most kind and most merciful.

I would like to express my thanks to **Dr. Iman Ibrahim**, Professor and Chairmen of Pediatric Nursing, Ain Shams University. I am indebted to her for giving me the privilege to work under her supervision. I appreciate her active participation in providing me with a lot of knowledge.

I would like to express my deep appreciation to **Dr. Mohsen**Saleh Elalphy, Professor and Chairmen of Pediatric Medicine, Ain
Shams University.

I would like to express my sincere thanks to **Dr. Madiha Amin Morsy**, Assistant. Professor of Pediatric Nursing, Ain Shams
University, for her valuable advice kind supervision, and continuous encouragement, support and guidance for the completion of this work.

🙇 Amira Adel Mohamed Nassar



My

Father. .

My

Brother & Sister

For Cheir Great Help, Encouragement, Love and Continuous Support

## List of Contents

Title	Page No.
List of tables	I
List of figures	II
Abstract	III
Introduction	1
Aim of the study	4
Research Hypothesis	4
Review of Literature	5
* Definition of anemia	5
* Pathophysiology	7
* Causes of hemolytic anemia	9
* Types of hemolytic anemia	11
* Thalassemia anemia	12
* Sickle cell anemia	15
* Symptoms of hemolytic anemia	16
* Laboratory diagnosis	19
* Complications of hemolytic anemia	20
* Treatment of hemolytic anemia	22
* Medical treatment for hemolytic anemia	23
* Blood transfusion	23
* Medications	24
* Iron therapy	24
* Chelation therapy	25
* Plasmapheresis	25
* Supplemental Oxygen	26

## Tist of Contents (Cont...)

Title	Page No.
* Surgerical treatment for hemolytic anemia	26
* Splenectomy	26
* Bone marrow or stem cell transplant	26
* Lifestyle changes	27
* Health education for parents of children with hemol anemia	•
* Protection from infection	28
* Clinical pathway	30
Subjects and Methods	41
Results	48
Discussion	77
Conclusion and Recommendations	85
Summary	86
References	
Appendices	1-9
Arabic Summary	

## Tist of Tables

Table No.	Title P	age No.
<b>Table</b> (1):	Distribution of both study and control grouchildren with hemolytic anemia by Demog characteristics.	raphic
<b>Table (2):</b>	Distribution of both study and control group implementation of clinical pathway of children's hemolytic anemia by their medical diagnose exposure to blood transfusion.	s with
<b>Table (3):</b>	Distribution of both the study and control grochildren's with hemolytic anemia according to frequency of hospitalization.	their
<b>Table (4):</b>	Distribution of both study and control grouchildren's with hemolytic anemia according to readmission after discharge.	their
<b>Table (5):</b>	Distribution of both study and control group children's with hemolytic anemia according to school attendance and reason of absenteeism	their
<b>Table (6):</b>	Distribution of both study and control grouchildren's according to their hereditary factor maternal history for hemolytic anemia	s and
<b>Table (7):</b>	Difference between study and control grouchildren's according to their blood tests implementation of clinical pathway	pre-
<b>Table (8):</b>	Difference between study and control grouchildren's according to their blood tests at implementation of clinical pathway.	initial
<b>Table (9):</b>	Difference between study and control grouchildren's according to their blood tests implementation of clinical pathway.	post
<b>Table (10):</b>	Difference between study and control grouchildren's according to their diagnostic tests implementation of clinical pathway	post

# Tist of Tables (Cont...)

Table Mo.	Title Page No.	
<b>Table</b> (11):	Difference between study and control group of children's according to their physiological examination pre- implementation of clinical pathway	59
<b>Table (12):</b>	Difference between study and control group of children's according to their physiological examination at initial implementation of clinical pathway6	50
<b>Table (13):</b>	Difference between study and control group of children's according to their physiological examination post implementation of clinical pathway.	51
<b>Table (14):</b>	Distribution of both study and control group of children's according to their complications pre-implementation of clinical pathway.	52
<b>Table (15):</b>	Distribution of both the study and control group of children's according to their complications at initial implementation of clinical pathway6	63
<b>Table (16):</b>	Distribution of both the study and control group of children's according to their complications post implementation of clinical pathway6	54
<b>Table (17):</b>	Significant difference in Physiological status of studied children pre and at initial implementation of clinical pathway.	55
<b>Table (18):</b>	Significant difference in Physiological status of studied children pre and post implementation of clinical pathway.	56
<b>Table (19):</b>	Significant difference in diagnostic tests of studied children pre and at initial implementation of clinical pathway6	57
<b>Table (20):</b>	Significant difference in diagnostic tests of studied children pre and post implementation of clinical pathway6	58
<b>Table (21):</b>	Significant difference in blood tests of studied children pre- and initial implementation of clinical pathway6	59

# Tist of Tables (Cont...)

Table No.	Title Page M	0.
<b>Table (22):</b>	Significant difference in blood tests of studied children pre- and post implementation of clinical pathway	70
<b>Table (23):</b>	Significant difference in physical and physiological children's status of studied children pre- and at initial implementation of clinical pathway.	71
<b>Table (24):</b>	Significant difference in physical and physiological children's status of studied children pre- and post implementation of clinical pathway.	72
<b>Table (25):</b>	Significant difference in treatments of studied children pre and at initial implementation of clinical pathway	73
<b>Table (26):</b>	Significant difference in treatments of studied children pre and post implementation of clinical pathway	74
<b>Table (27):</b>	Significant difference in nutritional status of studied children pre and post implementation of clinical pathway	75
<b>Table (28):</b>	Significant difference in activities of studied children pre and post implementation of clinical pathway	76

### List of Figures

Figures	Mo.	Title	Page No.
Fig. (1):	Shape of Normal Red B	lood Cells	6
Fig (2):	Shape of Thalassemia		14
Fig. (3):	Sickle Cell Anemia		15
Fig. (4):	Symptoms of Hemolytic	Anemia	18
Fig. (5a):	Bone marrow aspiration		19
Fig (5b):	Technique of blood trans	sfusion	23

#### **ABSTRACT**

The child suffering from hemolytic anemia is demanding and requiring the integration of skills from numerous different specialties. These children often have prolonged hospitalizations, which may be marked by many complications. In an attempt to provide and maintain a consistently high standard of care. Therefore the application of a clinical pathway for children with hemolytic anemia is urgent. Aim of study: This study was aimed to design, implement and evaluate the effect of a clinical pathway for children with hemolytic anemia. **Research design**: A quasi experimental research design was used in this study. **Settings:** The study was carried out at in-patient departments and out patient clinics in the pediatric hematological hospitals affiliated to Ain Shams University and Benha Children Hospital Subjects: A purposive sample composed of seventy (70) children with hemolytic anemia was recruited for the study. Half of the sample was considered as the study group those who were exposed to the clinical pathway and the control group who exposed to routine hospital care. **Tools:** Five tools were used for data collection: - questionnaire sheet, -Medical data sheet, - Patient assessment sheet, - Complication monitor sheet and **follow**l pathway design for the study group. **Results** of the study revealed that there was no statistically significant difference between the study and control groups on admission but there was a statistically significant difference between the study and control groups after the implementation of the clinical pathway for the study group compared with the routine hospital policy care for the control group manifested by less hospital stay, fewer complications and less readmissions. Conclusion: Children with hemolytic anemia to whom clinical pathway was applied fewer complications, less hospital stay and less readmission than those who will receive routine hospital care. **Recommendations:** Clinical pathway should be integrated into the routine nursing care along with intervention for children with hemolytic anemia.

**Key words:** Clinical pathway, Hemolytic anemia, Thalassemia, Sickle cell.



My

Father. .

My

Brother & Sister

For Cheir Great Help, Encouragement, Love and Continuous Support

#### **INTRODUCTION**

Anemia is the term which means that the number of red blood cells in a person's blood is less than normal or the red blood cells don't contain enough hemoglobin. Hemoglobin is an iron-rich protein in red blood cells that gives blood its red color (*Schwartz*, 2011).

Hemolytic anemia is a different form of anemia in which red blood cells are destroyed and removed from the bloodstream before their usual lifespan is up. Healthy red blood cells usually live about 120 days (4 months) in the bloodstream before the body removes them. In hemolytic anemia, the body breaks down and removes red blood cells faster than it can replace them; the breakdown of red blood cells is called hemolysis (*Vivek*, *2011*).

The most common type for children is hemolytic anemia. Types are inherited which means the child is born with them, one or more of the genes that control the production of red blood cells are defective causing the bone marrow to make abnormal cells. Acquired which means that they develop in response to some other disease or factor (*Brichard*, 2010).

Hemolytic anemia represents approximately 5% of all anemia worlds wide. Morbidity is dependent on the etiology of hemolytic anemia and the underlying disorder such as sickle cell anemia and Thalassemia (*Redd*, 2009).

Clinical pathway is a strategy that reduces resource utilization while maintaining the quality of care. The most popular methods intended to meet intense pressures to reduce the costs of health care .Clinical pathways are management plans that display goals for patients and provide the corresponding ideal sequence and timing of staff actions to achieve those goals with optimal efficiency (*Annie and Justin*, 2009).

Process of a developing a clinical pathway begins with the formation of health care team, making professionals from all sectors involved in a particular area. The team identifies the types of patients who require significant resources. Usually, this population is characterized by high cost, high volume or high risk. The team may also target such populations to decrease variability in physician practice (*Stephen*, *2010*).

Goals of pathways are to improve quality using printed standards of care, improve documentation of the care delivered, and improve communication about daily goals between all team members, patients and families, standardize inpatient chart format throughout the hospital, and increase efficiency of care. Pathway provides physicians and nurses with the standards of care and provides a mechanism for documentation at inpatient charts (*Neyens*, 2007).

Clinical pathway is a tool for achieving coordinated care and desired health outcomes within an anticipated time frame, by using the appropriate resources available. A clinical pathway is a blueprint that guides the clinician in the provision of care (*Blancett*, 2007).

#### **Significance of the Study:**

Children suffering from hemolytic anemia are demanding and requiring the integration of skills from numerous different specialties. These children often have prolonged hospitalizations, which may be marked by many complications, in an attempt to provide a consistently high standard of care as well as maintaining childe health. Therefore, the application of clinical pathway for children with hemolytic anemia is a necessary.